Pulmotect
PrivateLast Round
Series C
Sep 17, 2024
Total Funding Raised
$45.88M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Pulmotect operates in Healthcare & Life Sciences and is based in Houston, Texas. Its latest recorded funding round was a Series C round in September 2024.
Pulmotect is a biotechnology company developing PUL-042, a clinical-stage, inhaled therapeutic that stimulates the innate immune system to provide broad-spectrum protection against respiratory infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pulmotect Comparables
Compare Pulmotect with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ENA Respiratory | 83% | |
| NorthLinks Bio | 78% | |
| Synairgen plc | 73% |
For institutional investors. Book with your work email.
Pulmotect Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 17, 2024 | ||||
| Grant | May 30, 2023 | ||||
| Seed Round | Jan 26, 2022 | ||||
| Early Funding | Mar 5, 2021 | ||||
| Grant | Jan 27, 2021 | ||||
Series B | Apr 4, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Pulmotect Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fannin Innovation Studio | Series A, Series C, Series B |
| Jefferson River Capital | Series B |
| U.S. Department of War | Grant |
| National Heart, Lung, and Blood Institute | Grant |
| Axil Capital | Series C |
| Aquinas Companies, LLC | Series B |
| Cancer Prevention and Research Institute of Texas | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors grew 83% MoM, reaching 1.6K.
- Sep 17, 2024
$6M round led by Fannin Innovation Studio.
For institutional investors. Book with your work email.
Pulmotect Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Pulmotect's valuation, stock price, and market status.
Is Pulmotect a public or private company?
Pulmotect is a private company.
What is the current stock price of Pulmotect?
Pulmotect is a private company, so its shares have no public market price. Caplight tracks Pulmotect's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Pulmotect worth (valuation)?
Valuation information for Pulmotect is not publicly available.
Can I buy Pulmotect stock?
Pulmotect shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Pulmotect's last funding round?
Pulmotect's most recent funding round was Series C on September 17, 2024.
Who are the main investors in Pulmotect?
Key investors in Pulmotect include Fannin Innovation Studio.
Will Pulmotect IPO soon?
No public IPO plans have been announced for Pulmotect.
How can I track Pulmotect secondary market activity?
Caplight tracks bids, offers, and trades in Pulmotect's shares on secondary markets.